z-logo
Premium
Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem‐cell transplantation: Report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo Osseo
Author(s) -
Alessandrino Emilio Paolo,
Angelucci Emanuele,
Cazzola Mario,
Porta Matteo Giovanni Della,
Di Bartolomeo Paolo,
Gozzini Antonella,
Malcovati Luca,
Pioltelli Pietro,
Sica Simona,
Bosi Alberto
Publication year - 2011
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.22104
Subject(s) - medicine , myelodysplastic syndromes , deferasirox , transplantation , chelation therapy , intensive care medicine , thalassemia , bone marrow
Many myelodysplastic syndrome (MDS) patients have a long history of transfusion before eventually undergoing transplantation and therefore are at high risk of developing parenchymal iron overload. Recently, retrospective studies suggested that iron overload has some prognostic impact in MDS patients treated by allogeneic stem-cell transplantation (allo-SCT) as previously observed in thalassemia. However, the optimal strategy to assess iron overload and to reduce iron burden during and after transplant procedure remains to be determined. The Gruppo Italiano Trapianto di Midollo Osseo (GITMO) promoted a consensus process aimed at providing clinical practice recommendations that can support the appropriate choice for iron overload assessment and for iron chelation therapy in MDS patients undergoing allo-SCT. A systematic review of the published literature (1990–2010) was performed. An Expert Panel was selected according to the framework elements of the NIH Consensus Development Program, comprising 10 physicians with different areas of expertise (iron metabolism, SCT, and MDS patient management/treatment). Based on the available scientific evidence and consensus among experts, clinical recommendations were formulated on appropriate assessment of iron body stores, selection of candidates to iron chelation therapy before and after allo-SCT, and treatment modalities

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here